⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for splenic marginal zone lymphoma

Every month we try and update this database with for splenic marginal zone lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaNCT00019708
Extranodal Marg...
Nodal Marginal ...
Non-Hodgkin Lym...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
tanespimycin
19 Years - National Cancer Institute (NCI)
Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's LymphomaNCT00003639
Lymphoma
recombinant int...
chlorambucil
dexamethasone
idarubicin
15 Years - 70 YearsNational Cancer Institute (NCI)
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell TransplantationNCT00003056
Leukemia
Lymphoma
Graft Versus Ho...
cyclosporine
cyclosporine an...
18 Years - 55 YearsTakeda
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative DiseaseNCT00176475
Leukemia
Lymphoma
Multiple Myelom...
rituximab
therapeutic all...
18 Years - Rutgers, The State University of New Jersey
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell TransplantationNCT00003143
Lymphoma
Amifostine
DHAP
18 Years - Jonsson Comprehensive Cancer Center
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's LymphomaNCT00244946
Lymphoma
therapeutic aut...
carmustine
cytarabine
etoposide
melphalan
peripheral bloo...
15 Years - 70 YearsBarbara Ann Karmanos Cancer Institute
Bone Marrow Transplantation in Treating Patients With LymphomaNCT00002829
Lymphoma
Recombinant Int...
Cyclophosphamid...
Etoposide
Mesna
Bone Marrow Tra...
Radiation Thera...
15 Years - 60 YearsM.D. Anderson Cancer Center
Beta Alethine in Treating Patients With Low-Grade LymphomaNCT00007839
Lymphoma
beta alethine
18 Years - National Cancer Institute (NCI)
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00119392
B-cell Chronic ...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Waldenström Mac...
rituximab
cyclosporine
fludarabine pho...
mycophenolate m...
yttrium Y 90 ib...
peripheral bloo...
allogeneic hema...
total-body irra...
18 Years - Fred Hutchinson Cancer Center
Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative DiseaseNCT01720758
Hairy Cell Leuk...
Splenic Margina...
18 Years - HaEmek Medical Center, Israel
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent LymphomaNCT00980395
Lymphoma
Mantle Cell Lym...
Indolent Lympho...
SLL
rituximab
bortezomib
cladribine
18 Years - University of Arizona
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaNCT00265928
Lymphoma
bortezomib
rituximab
antibody therap...
biological ther...
enzyme inhibito...
monoclonal anti...
18 Years - National Cancer Institute (NCI)
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's LymphomaNCT00101244
Adult Grade III...
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
ispinesib
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202NCT00896662
Lymphoma
Solid Tumor
immunologic tec...
laboratory biom...
pharmacological...
18 Years - Vanderbilt-Ingram Cancer Center
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's LymphomaNCT00397800
Lymphoma
rituximab
cyclophosphamid...
fludarabine pho...
yttrium Y 90 ib...
50 Years - 75 YearsTechnical University of Munich
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's LymphomaNCT00005601
Lymphoma
rituximab
cisplatin
cytarabine
dexamethasone
sargramostim
18 Years - Alliance for Clinical Trials in Oncology
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's LymphomaNCT00007852
Lymphoma
rituximab
carmustine
cytarabine
etoposide
melphalan
autologous hema...
19 Years - University of Nebraska
Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's LymphomaNCT00006039
Lymphoma
Small Intestine...
pegylated inter...
18 Years - Memorial Sloan Kettering Cancer Center
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's LymphomaNCT00278161
Leukemia
Lymphoma
Pegfilgrastim
Rituximab
Cyclophosphamid...
18 Years - 70 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic MalignancyNCT00891137
Leukemia
Lymphoma
Multiple Myelom...
Plasma Cell Neo...
Myelodysplastic...
human myeloid p...
12 Years - 65 YearsCellerant Therapeutics
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's LymphomaNCT00004192
Lymphoma
Neutropenia
filgrastim
pegfilgrastim
cisplatin
cytarabine
etoposide
methylprednisol...
18 Years - 120 YearsUniversity of Nebraska
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell CancersNCT00003163
Lymphoma
Multiple Myelom...
filgrastim
sargramostim
cyclophosphamid...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - National Cancer Institute (NCI)
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionNCT00118170
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Mult...
Splenic Margina...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
sorafenib tosyl...
pharmacological...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's LymphomaNCT00007865
Lymphoma
rituximab
carboplatin
etoposide
ifosfamide
19 Years - 120 YearsUniversity of Nebraska
Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's LymphomaNCT00002697
Lymphoma
filgrastim
sargramostim
carboplatin
etoposide
ifosfamide
autologous bone...
bone marrow abl...
peripheral bloo...
radiation thera...
18 Years - 65 YearsMemorial Sloan Kettering Cancer Center
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00244985
Lymphoma
rituximab
pegylated lipos...
18 Years - 120 YearsRoswell Park Cancer Institute
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic CancerNCT00003661
Graft Versus Ho...
Leukemia
Lymphoma
Myelodysplastic...
Neuroblastoma
anti-thymocyte ...
busulfan
cyclosporine
melphalan
methylprednisol...
umbilical cord ...
radiation thera...
- 54 YearsRoswell Park Cancer Institute
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's LymphomaNCT00110149
Lymphoma
rituximab
yttrium Y 90 ib...
18 Years - 120 YearsBeth Israel Deaconess Medical Center
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaNCT01812005
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
alisertib
rituximab
laboratory biom...
18 Years - Ohio State University Comprehensive Cancer Center
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell TransplantationNCT00003143
Lymphoma
Amifostine
DHAP
18 Years - Jonsson Comprehensive Cancer Center
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's LymphomaNCT00082823
Cancer
ziv-aflibercept
18 Years - 120 YearsRegeneron Pharmaceuticals
Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaNCT00002908
Leukemia
Lymphoma
bryostatin 1
vincristine sul...
18 Years - Barbara Ann Karmanos Cancer Institute
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin LymphomaNCT00784927
Lymphoma
rituximab
cyclophosphamid...
dexamethasone
lenalidomide
18 Years - 120 YearsMayo Clinic
Rituximab Plus Interleukin-2 in Treating Patients With LymphomaNCT00003356
Lymphoma
aldesleukin
rituximab
18 Years - 75 YearsUniversity of Rochester
Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)NCT00005626
Leukemia
Lymphoma
Irinotecan
18 Years - H. Lee Moffitt Cancer Center and Research Institute
Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid LeukemiaNCT00017472
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Margi...
Recurrent Small...
Refractory Chro...
Splenic Margina...
Stage III Margi...
Stage III Small...
Stage IV Margin...
Stage IV Small ...
apolizumab
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's LymphomaNCT00088881
Contiguous Stag...
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Splenic Margina...
Stage I Adult D...
Testicular Lymp...
Waldenström Mac...
rituximab
prednisone
cyclophosphamid...
doxorubicin
vincristine
indium In 111 i...
radiation thera...
positron emissi...
18 Years - National Cancer Institute (NCI)
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic CancersNCT00003572
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
peripheral bloo...
mycophenolate m...
tacrolimus
allogeneic bone...
radiation thera...
18 Years - 70 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or LeukemiaNCT00005786
Extranodal Marg...
Nodal Marginal ...
Prolymphocytic ...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Small...
Refractory Chro...
Splenic Margina...
Waldenström Mac...
arsenic trioxid...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic LymphomaNCT00608374
Lymphoma
chlorambucil
fludarabine pho...
quality-of-life...
18 Years - National Cancer Institute (NCI)
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin LymphomaNCT01239875
Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Adult Diffuse M...
Adult Diffuse S...
Adult Grade III...
Adult Immunobla...
Adult Lymphobla...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3 Follicu...
Mantle Cell Lym...
Marginal Zone L...
Small Lymphocyt...
Splenic Margina...
Waldenstrom Mac...
dendritic cell ...
cryotherapy
pneumococcal po...
laboratory biom...
immunoenzyme te...
immunohistochem...
autologous dend...
18 Years - 90 YearsMayo Clinic
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionNCT00118170
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Mult...
Splenic Margina...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
sorafenib tosyl...
pharmacological...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic SyndromeNCT00002989
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
busulfan
cyclophosphamid...
idarubicin
melphalan
radiation thera...
16 Years - 60 YearsNational Cancer Institute (NCI)
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00040950
Lymphoma
rituximab
agatolimod sodi...
18 Years - National Cancer Institute (NCI)
Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaNCT00062296
Leukemia
Lymphoma
rituximab
epirubicin hydr...
18 Years - Fox Chase Cancer Center
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin LymphomaNCT01239875
Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Adult Diffuse M...
Adult Diffuse S...
Adult Grade III...
Adult Immunobla...
Adult Lymphobla...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3 Follicu...
Mantle Cell Lym...
Marginal Zone L...
Small Lymphocyt...
Splenic Margina...
Waldenstrom Mac...
dendritic cell ...
cryotherapy
pneumococcal po...
laboratory biom...
immunoenzyme te...
immunohistochem...
autologous dend...
18 Years - 90 YearsMayo Clinic
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin LymphomaNCT00691652
Lymphoma
rituximab
clofarabine
DNA methylation...
gene expression...
microarray anal...
polymerase chai...
high performanc...
laboratory biom...
18 Years - 89 YearsOHSU Knight Cancer Institute
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaNCT01045928
Adult Non-Hodgk...
Adult Grade III...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage I Adult B...
Stage I Adult D...
Stage I Adult D...
Stage I Adult D...
Stage I Adult I...
Stage I Adult L...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Waldenstrom Mac...
lenalidomide
rituximab
polymerase chai...
nucleic acid se...
polymorphism an...
flow cytometry
laboratory biom...
18 Years - Case Comprehensive Cancer Center
UCN-01 in Treating Patients With Advanced CancerNCT00003289
Leukemia
Lymphoma
Unspecified Adu...
7-hydroxystauro...
18 Years - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's LymphomaNCT00110071
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
fludarabine pho...
peripheral bloo...
iodine I 131 to...
laboratory biom...
flow cytometry
polymerase chai...
60 Years - Fred Hutchinson Cancer Center
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic CancerNCT00010192
B-cell Adult Ac...
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
rituximab
aldesleukin
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaNCT02281279
B-cell Adult Ac...
Extranodal Marg...
Intraocular Lym...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Hair...
Small Intestine...
Splenic Margina...
Testicular Lymp...
Waldenström Mac...
rituximab
lenalidomide
romidepsin
laboratory biom...
18 Years - Mayo Clinic
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic CancerNCT00296023
Chronic Myelopr...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
anti-thymocyte ...
filgrastim
therapeutic all...
busulfan
fludarabine pho...
methotrexate
tacrolimus
nonmyeloablativ...
peripheral bloo...
18 Years - 75 YearsUniversity of California, San Francisco
PS-341 in Treating Patients With Advanced CancerNCT00006362
Leukemia
Lymphoma
Multiple Myelom...
Precancerous Co...
Unspecified Adu...
bortezomib
18 Years - Mayo Clinic
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By ChemotherapyNCT00003341
Anemia
Leukemia
Lymphoma
Multiple Myelom...
epoetin alfa
quality-of-life...
18 Years - Memorial Sloan Kettering Cancer Center
Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or LymphomaNCT00006252
Leukemia
Lymphoma
fludarabine pho...
Cyclophosphamid...
PBSC
G-CSF
Donor lymphocyt...
- 69 YearsAlliance for Clinical Trials in Oncology
Bone Marrow Transplantation in Treating Patients With LymphomaNCT00002829
Lymphoma
Recombinant Int...
Cyclophosphamid...
Etoposide
Mesna
Bone Marrow Tra...
Radiation Thera...
15 Years - 60 YearsM.D. Anderson Cancer Center
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00005592
Lymphoma
90-Y-ibritumoma...
rituximab
indium In 111 i...
18 Years - University of Alabama at Birmingham
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaNCT02049541
Extranodal Marg...
Nodal Marginal ...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
PI3K inhibitor ...
rituximab
Pharmacodynamic...
Correlative stu...
18 Years - Ohio State University Comprehensive Cancer Center
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00040950
Lymphoma
rituximab
agatolimod sodi...
18 Years - National Cancer Institute (NCI)
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic CancerNCT00003661
Graft Versus Ho...
Leukemia
Lymphoma
Myelodysplastic...
Neuroblastoma
anti-thymocyte ...
busulfan
cyclosporine
melphalan
methylprednisol...
umbilical cord ...
radiation thera...
- 54 YearsRoswell Park Cancer Institute
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's LymphomaNCT00110071
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
fludarabine pho...
peripheral bloo...
iodine I 131 to...
laboratory biom...
flow cytometry
polymerase chai...
60 Years - Fred Hutchinson Cancer Center
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00073918
Anaplastic Larg...
Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
cyclophosphamid...
etoposide
iodine I 131 to...
quality-of-life...
peripheral bloo...
18 Years - 60 YearsFred Hutchinson Cancer Center
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin LymphomaNCT00551239
Leukemia
Lymphoma
rituximab
fludarabine pho...
pixantrone dima...
18 Years - 120 YearsCTI BioPharma
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent LymphomaNCT00980395
Lymphoma
Mantle Cell Lym...
Indolent Lympho...
SLL
rituximab
bortezomib
cladribine
18 Years - University of Arizona
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or LeukemiaNCT00019838
Leukemia
Lymphoma
7-hydroxystauro...
fludarabine pho...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's LymphomaNCT00003639
Lymphoma
recombinant int...
chlorambucil
dexamethasone
idarubicin
15 Years - 70 YearsNational Cancer Institute (NCI)
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell NeoplasmsNCT00082784
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Refractory Plas...
Splenic Margina...
Waldenstrom Mac...
Bortezomib
Alvocidib Hydro...
Pharmacological...
18 Years - National Cancer Institute (NCI)
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell CancersNCT00003163
Lymphoma
Multiple Myelom...
filgrastim
sargramostim
cyclophosphamid...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - National Cancer Institute (NCI)
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's LymphomaNCT00004192
Lymphoma
Neutropenia
filgrastim
pegfilgrastim
cisplatin
cytarabine
etoposide
methylprednisol...
18 Years - 120 YearsUniversity of Nebraska
Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's MacroglobulinemiaNCT00004107
Leukemia
Lymphoma
filgrastim
autologous bone...
peripheral bloo...
indium In 111 m...
yttrium Y 90 ep...
18 Years - 80 YearsGarden State Cancer Center at the Center for Molecular Medicine and Immunology
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaNCT00275080
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Blastic Phase C...
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Secondary Acute...
Splenic Margina...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Untreated Adult...
Untreated Adult...
vorinostat
decitabine
18 Years - National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00012298
Extranodal Marg...
Nodal Marginal ...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Waldenström Mac...
rituximab
yttrium Y 90 ib...
indium In 111 i...
oprelvekin
filgrastim
18 Years - National Cancer Institute (NCI)
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin LymphomaNCT00621452
B-cell Chronic ...
Extranodal Marg...
Nodal Marginal ...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Chro...
Splenic Margina...
Waldenström Mac...
therapeutic aut...
cyclophosphamid...
aldesleukin
polymerase chai...
gene rearrangem...
lymph node biop...
genetically eng...
bone marrow asp...
flow cytometry
laboratory biom...
enzyme-linked i...
- Fred Hutchinson Cancer Center
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaNCT02049541
Extranodal Marg...
Nodal Marginal ...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
PI3K inhibitor ...
rituximab
Pharmacodynamic...
Correlative stu...
18 Years - Ohio State University Comprehensive Cancer Center
Tipifarnib in Treating Patients With Advanced Hematologic CancerNCT00005967
Chronic Myelopr...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
tipifarnib
18 Years - National Cancer Institute (NCI)
Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL PatientsNCT05735834
Splenic Margina...
Rituximab
Zanubrutinib
18 Years - International Extranodal Lymphoma Study Group (IELSG)
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's LymphomaNCT00003605
Lymphoma
rituximab
cyclophosphamid...
- Hoag Memorial Hospital Presbyterian
Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's LymphomaNCT00387959
Leukemia
Lymphoma
filgrastim
rituximab
cyclophosphamid...
cyclosporine
fludarabine pho...
mycophenolate m...
allogeneic hema...
umbilical cord ...
total-body irra...
18 Years - 70 YearsMemorial Sloan Kettering Cancer Center
UCN-01 in Treating Patients With Advanced CancerNCT00003289
Leukemia
Lymphoma
Unspecified Adu...
7-hydroxystauro...
18 Years - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: